Introduction {#H1-1-ZOI200369}
============

Thyroid cancer is the most pervasive endocrine cancer worldwide.^[@zoi200369r1]^ During the past decades, published studies reported that the incidence of thyroid cancer continues to increase^[@zoi200369r2]^ in countries and regions such as Canada,^[@zoi200369r3]^ the US,^[@zoi200369r4]^ Australia,^[@zoi200369r5]^ Asia,^[@zoi200369r6],[@zoi200369r7],[@zoi200369r8]^ South America,^[@zoi200369r9]^ and Europe.^[@zoi200369r10],[@zoi200369r11],[@zoi200369r12],[@zoi200369r13]^ Although some regional studies have provided data on the incidence and mortality associated with thyroid cancer,^[@zoi200369r14],[@zoi200369r15]^ studies on thyroid cancer examining the association between the disease and country, sex, age, sociodemographic index (SDI), and other factors are lacking. Comprehensive, in-depth analysis of thyroid cancer in all regions of the world based on a variety of factors may be beneficial for health care planning and resource allocation.

The Global Health Data Exchange is a public website available for querying the burden of 354 human diseases and injuries in 195 countries and territories worldwide, providing an opportunity to investigate the distribution and changes in the patterns of thyroid cancer.^[@zoi200369r16]^ Analyses based on age-standardized rates may help policy makers assess the burden of thyroid cancer, measure the progress of specific treatments, allocate resources, and formulate relevant policies. This study aimed to explore the current pattern and alteration of thyroid cancer incidence, deaths, and disability-adjusted life-years (DALYs).

Methods {#H1-2-ZOI200369}
=======

Study Population and Data Collection {#H2-1-ZOI200369}
------------------------------------

The data were obtained using the Global Health Data Exchange, covering annual incidence, deaths, DALYs, and age-standardized rate of thyroid cancer in 21 regions and 195 countries, from January 1, 1990, to December 31, 2017.^[@zoi200369r17]^ Data on both sexes of 4 age groups (5-14, 15-49, 50-69, and ≥70 years) were collected. Detailed descriptions of the methods are presented in the eAppendix in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}. Data analysis was completed on October 1, 2019. To consider the association between development status and thyroid cancer burden, the SDI of each country was calculated in the Global Burden of Disease Study (GBD) 2017.^[@zoi200369r18]^ Sociodemographic index is a comprehensive measurement of educational level, income per capita, and fertility rate, with scores ranging from 0 to 1. Countries were divided into 5 SDI quintiles (high, high-middle, middle, low-middle, and low). We analyzed the thyroid cancer data at the global, regional, and national levels among different SDI, sex, and age groups.

The institutional review board of the First Affiliated Hospital of Zhejiang University in Zhejiang Province, Hangzhou, China, determined that the study did not need approval because it used publicly available data. This study followed the Guidelines for Accurate and Transparent Health Estimates Reporting ([GATHER](https://www.equator-network.org/reporting-guidelines/gather-statement/)) reporting guideline for cross-sectional studies.^[@zoi200369r19]^

Statistical Analysis {#H2-2-ZOI200369}
--------------------

The age-standardized rates and their estimated annual percentage changes (EAPCs) were calculated to assess the incidence and mortality trends of thyroid cancer using linear regression analysis, and Pearson product-moment correlation analysis was performed to assess correlation. All rates are reported per 100 000 person-years.

The trends of age-standardized rates were reflected in EAPC values: age-standardized rate is in an upward trend when the EAPCs and the lower boundary of the 95% CI are positive; conversely, age-standardized rate is in a downward trend when EAPCs and the upper boundary of the 95% CI are negative. DisMod-MR, version, 2.1, a bayesian meta-regression framework, was used in modeling epidemiologic outcomes and ascertaining the burden of thyroid cancer in different regions, sexes, countries, and age groups. Moreover, the correlation between EAPCs and age-standardized rate in 1990 as well as SDI in 2017 in different countries was evaluated with Pearson correlation analyses to define the potential factors affecting EAPCs. Statistical analyses were performed using R, version 3.5.2 (R Project for Statistical Computing). A 2-tailed *P* value \<.05 was considered statistically significant.

Results {#H1-3-ZOI200369}
=======

Thyroid Cancer Worldwide {#H2-3-ZOI200369}
------------------------

Globally, there were 95 030 incident cases of thyroid cancer (95% uncertainty interval \[UI\], 90 070-100 720 cases) and 22 070 deaths (95% UI, 20 810-24 220 deaths) in 1990 and 255 490 incident cases (95% UI, 245 710-272 470 cases) and 41 240 deaths (95% UI, 39 910-44 140 deaths) in 2017 ([Table](#zoi200369t1){ref-type="table"}). In total, thyroid cancer was responsible for 1 133 170 DALYs (95% UI, 1 073 440-1 277 490 DALYs) in 2017. From 1990 to 2017, increases were noted in incident cases (169%), deaths (87%), and DALYs (75%) of thyroid cancer. In addition, the age-standardized rates ([Figure 1](#zoi200369f1){ref-type="fig"}) and their changing trends varied among different countries ([Figure 2](#zoi200369f2){ref-type="fig"}). The age-standardized incidence rate (ASIR) showed an upward trend worldwide (EAPC, 1.59; 95% CI, 1.51-1.67), while age-standardized death rate (ASDR) (EAPC, −0.15; 95% CI, −0.19 to −0.12) and age-standardized DALY rate (EAPC, −0.11; 95% CI, −0.15 to −0.08) presented a downward trend (eTable 1 and eTable 2 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). In addition, the ASIR for both sexes (males: EAPC, 2.18; 95% CI, 2.07-2.28; females: EAPC, 1.38; 95% CI, 1.30-1.46) as well as ASDR (EAPC, 0.70; 95% CI, 0.61-0.78) and age-standardized DALY rate (EAPC, 0.59; 95% CI, 0.52-0.66) for males continued to increase, whereas the ASDR (EAPC, −0.63; 95% CI, −0.66 to −0.59) and age-standardized DALY rate (EAPC, −0.53; 95% CI, −0.57 to −0.48) for females showed a decreasing trend.

###### Incidence of Thyroid Cancer and Trends From 1990 to 2017

  Characteristics                1990                      2017   1990-2017                                                                               
  ------------------------------ ------------------------- ------ ------------------- ------ --------------------------- ------ ------------------ ------ -----------------------
  Overall                        95 030 (90 070-100 720)   1.92   2.11 (2.01-2.24)    2.65   255 490 (245 710-272 470)   2.36   3.15 (3.03-3.36)   2.23   1.59 (1.51-1.67)
  Sex                                                                                                                                                     
  Male                           24 170 (23 330-25 210)    NA     1.15 (1.11-1.19)    NA     76 090 (72 580-79 290)      NA     1.94 (1.86-2.02)   NA     2.18 (2.07-2.28)
  Female                         70 850 (66 090-76 420)    NA     3.04 (2.85-3.28)    NA     179 400 (170 400-195 540)   NA     4.34 (4.12-4.73)   NA     1.38 (1.30-1.46)
  Sociodemographic index                                                                                                                                  
  Low                            5710 (3970-7390)          1.84   1.23 (0.90-1.58)    2.97   15 400 (13 730-17 480)      3.21   1.63 (1.46-1.85)   2.79   1.01 (0.88-1.13)
  Low-middle                     9650 (8290-11 620)        2.01   1.28 (1.12-1.54)    3.36   31 540 (28 460-36 750)      3.58   2.14 (1.95-2.47)   3.13   1.91 (1.84-1.98)
  Middle                         15 470 (14 500-17 770)    1.90   1.31 (1.24-1.52)    2.98   60 930 (57 100-69 460)      2.46   2.61 (2.45-2.97)   2.33   2.65 (2.54-2.75)
  High-middle                    20 990 (19 080-22 130)    1.94   2.03 (1.87-2.14)    3.05   58 680 (55 410-62 290)      2.38   3.30 (3.12-3.50)   2.28   1.81 (1.64-1.98)
  High                           42 950 (42 080-43 830)    1.92   3.66 (3.58- 3.73)   2.19   88 070 (85 080-91 930)      1.91   5.17 (4.98-5.42)   1.88   1.61 (1.33-1.89)
  Region                                                                                                                                                  
  Andean Latin America           420 (370-490)             2.40   1.67 (1.50-1.92)    3.49   2350 (2020-2680)            3.93   4.12 (3.56-4.70)   3.73   3.69 (3.29-4.09)
  Australasia                    640 (600-690)             1.56   2.82 (2.61-3.03)    1.77   2030 (1770-2310)            1.85   5.29 (4.61-6.04)   1.74   2.87 (2.68-3.05)
  Caribbean                      560 (520-600)             1.85   1.94 (1.79-2.08)    3.06   1440 (1300-1600)            2.57   2.86 (2.58-3.16)   2.40   1.53 (1.30-1.77)
  Central Asia                   1020 (930-1160)           1.79   1.88 (1.71-2.13)    2.82   1740 (1610-1900)            3.47   2.01 (1.85-2.18)   2.86   −0.11 (−0.56 to 0.34)
  Central Europe                 4810 (4620-5010)          1.77   3.28 (3.14-3.42)    2.86   650 (6110-6950)             3.32   3.77 (3.54-4.06)   3.16   0.40 (0.27-0.54)
  Central Latin America          2030 (1960-2110)          2.14   1.95 (1.89-2.02)    3.35   8520 (8090-9030)            3.84   3.44 (3.27-3.65)   3.38   1.93 (1.81-2.05)
  Central sub-Saharan Africa     200 (150-270)             1.98   0.71 (0.57-0.92)    2.56   480 (380-680)               2.84   0.74 (0.59-1.04)   2.31   0.02 (−0.14 to 0.18)
  East Asia                      12 090 (10 540-13 220)    1.69   1.11 (0.99-1.22)    2.98   44 770 (41 550-50 710)      1.58   2.22 (2.06-2.53)   1.56   2.66 (2.31-3.01)
  Eastern Europe                 7850 (7250-8780)          2.40   2.88 (2.67-3.22)    2.53   14 500 (13 610-15530)       3.40   5.03 (4.70-5.40)   2.69   2.19 (1.88-2.51)
  Eastern sub-Saharan Africa     1990 (1340-2640)          1.86   1.75 (1.24-2.28)    2.66   4590 (3910-5460)            2.57   1.84 (1.59-2.15)   2.01   −0.01 (−0.15 to 0.14)
  High-income Asia Pacific       6680 (6400-7020)          2.08   3.25 (3.11-3.41)    3.10   20 620 (18 890-22 710)      2.69   7.21 (6.50-8.08)   2.81   4.43 (3.69-5.18)
  High-income North America      11 980 (11 670-12 320)    1.48   3.68 (3.59-3.79)    1.52   28 280 (27 190-29 350)      1.53   5.44 (5.22-5.65)   1.47   1.32 (1.06-1.57)
  North Africa and Middle East   3560 (2890-4410)          1.68   1.56 (1.27-1.96)    3.67   17 470 (15 990-19 890)      3.10   3.19 (2.93-3.65)   3.20   2.98 (2.86-3.11)
  Oceania                        70 (50-80)                1.81   1.74 (1.45-2.09)    2.87   190 (140-230)               2.90   2.14 (1.70-2.65)   2.98   0.73 (0.57-0.90)
  South Asia                     10 540 (8750-12 910)      1.88   1.25 (1.06-1.52)    3.37   37 970 (33 680-43 030)      3.55   2.29 (2.03-2.58)   3.30   2.30 (2.16-2.43)
  Southeast Asia                 6840 (5860-7840)          2.40   2.12 (1.82-2.47)    3.20   23 880 (21 430-29 120)      3.40   3.55 (3.21-4.33)   2.99   2.00 (1.95-2.04)
  Southern Latin America         1100 (1030-1180)          1.82   2.31 (2.16-2.47)    2.57   2310 (2090-2590)            2.76   3.06 (2.75-3.44)   2.47   0.85 (0.66-1.04)
  Southern Sub-Saharan Africa    390 (330-430)             2.07   1.09 (0.94-1.20)    3.05   760 (680-860)               2.95   1.16 (1.05-1.32)   2.36   −0.10 (−0.58 to 0.39)
  Tropical Latin America         1830 (1750-1910)          2.79   1.65 (1.59-1.72)    2.48   5540 (5270-5770)            2.31   2.28 (2.17-2.38)   2.02   1.19 (1.00-1.38)
  Western Europe                 19 900 (19 190-20 630)    2.07   3.99 (3.85-4.14)    2.31   30 260 (28 580-32 030)      1.73   4.57 (4.31-4.87)   1.68   0.58 (0.36-0.80)
  Western sub-Saharan Africa     530 (410-610)             1.57   0.49 (0.38-0.57)    2.29   1300 (1110-1560)            2.46   0.55 (0.47-0.66)   1.91   0.39 (0.30-0.47)

Abbreviations: ASIR, age-standardized incidence rate; EAPC, estimated annual percentage change; NA, not available; UI, uncertainty interval.
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The 3 countries with the highest incident cases of thyroid cancer were the same from the beginning to the end of the study: China (11 016 in 1990 and 41 511 in 2017), the US (10 833 in 1990 and 25 896 in 2017), and India (7369 in 1990 and 25 675 in 2017) (eTable 3 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). China had the highest number of deaths associated with thyroid cancer worldwide (3109; 95% UI, 2890-3636 in 1990; 6801; 95% UI, 6381-7433 in 2017) (eTable 4 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). The country with the highest thyroid cancer DALYs changed from China (97 404.96; 95% CI, 89 652.29-110 236.18) in 1990 to India (202 323.54; 95% CI, 181 444.20-220 531.59) in 2017 (eTable 5 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

Thyroid Cancer Incidence {#H2-4-ZOI200369}
------------------------

At a global level, from 1990 to 2017, thyroid cancer ASIR in most countries presented an upward trend ([Figure 1](#zoi200369f1){ref-type="fig"}A). Incident cases were greater among females than among males (female to male ratio, 1.92 in 1990 and 2.36 in 2017), as was the ASIR of thyroid cancer (female to male ratio, 2.65 in 1990 and 2.23 in 2017); however, the EAPC was larger in males (2.18; 95% CI, 2.07-2.28) than in females (EAPC, 1.38; 95% CI, 1.30-1.46) ([Table](#zoi200369t1){ref-type="table"}). As reported in eTable 3 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}, the country with the highest ASIR changed from Iceland in 1990 (total: 30.18; 95% UI, 27.26-33.49; females: 15.64; 95% UI, 13.49-17.76; males: 6.97; 95% UI, 5.93-8.11) to South Korea in 2017 (total: 12.87; 95% UI, 11.04-15.23; females: 19.85; 95% UI, 16.41-24.29). However, the ASIR among males in Iceland was still the highest in 2017 (12.31; 95% UI, 10.22-14.80). The ASIR decreased the most in Qatar (total: EAPC, −2.50; 95% CI, −2.96 to −2.04; females: EAPC, −3.34; 95% CI, −4.01 to −2.67) and increased the most in South Korea (total: EAPC, 10.70; 95% CI, 8.85-12.59; females: EAPC, 11.05; 95% CI, 9.06-13.08; males: EAPC, 10.26; 95% CI, 8.87-11.67). The ASIR among males decreased most in Kazakhstan (EAPC, −2.25; 95% CI, −2.65 to −1.83). In addition, the EAPC was negatively correlated with ASIR (ρ = −0.18, *P* = .01) ([Figure 3](#zoi200369f3){ref-type="fig"}A) and positively associated with SDI (ρ = 0.21, *P* \< .01) (eFigure 1 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). The incident cases of thyroid cancer varied greatly among different regions. The region with the largest number of incident cases had changed from Western Europe (19 900; 95% UI, 19 190-20 630) in 1990 to East Asia (44 770; 95% UI, 41 550-50 710) in 2017. Oceania had the smallest number of incident cases (70; 95% UI, 50-80 in 1990 and 190; 95% UI, 140-230 in 2017) ([Table](#zoi200369t1){ref-type="table"}). The ASIR increased most in high-income Asia Pacific among females (EAPC, 4.43; 95% CI, 3.69-5.18) and in East Asia for males (EAPC, 5.01; 95% CI, 4.56-5.47) (eTable 6 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).
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A third (34%) of patients with thyroid cancer resided in countries with a high SDI. As for various SDI quintiles, the fastest growth of ASIR was in the middle SDI quintile (EAPC, 2.65; 95% CI, 2.54-2.75) ([Table](#zoi200369t1){ref-type="table"}). Previously, in both females and males, the countries with high SDI had the highest thyroid cancer incident cases (42 950 in 1990 and 88 070 in 2017) and ASIR (3.66 in 1990 and 5.17 in 2017), whereas the low SDI countries had the lowest (5710 in 1990 and 15 400 in 2017; 1.23 in 1990 and 1.63 in 2017) (eTable 6 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). In addition, patients with thyroid cancer in the high SDI quintile were mostly aged 50 to 69 years (all ages, incident cases: 88070; 95% CI, 85081-91934); age 50-69 years, incident cases: 41666; 95% CI, 39921-43409), while those in the low (all ages, incident cases: 15404; 95% CI, 13734-17481); age 15-49 years, incident cases:9493; 95% CI, 8331-10916) and low-middle (all ages, incident cases: 31536; 95% CI, 28461-36747); age 15-49 years, incident cases: 19128; 95% CI,16514-22873) SDI quintiles were mostly aged 15 to 49 years (incident cases proportion of age 50-69 years in high SDI compared with that in the other 4 quintiles, *P* \< .05) (eFigures 2-7 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). Although the EAPC was positive (1.61; 95% CI, 1.33-1.89), the ASIR of the high SDI quintile started decreasing from 2010 among both females and males. The ASIR in the other 4 SDI quintiles (high-middle, middle, low-middle, and low) continued to increase over time ([Figure 4](#zoi200369f4){ref-type="fig"}). As for the age of individuals with thyroid cancer, the disease remained concentrated in the subgroup aged 15 to 69 years (eFigure 8 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

![Change Trends of Thyroid Cancer Age-Standardized Incidence Rate Among Sex and Sociodemographic Index (SDI) Quintiles\
Changes shown in overall (A), females (B), and males (C) trends.](jamanetwopen-3-e208759-g004){#zoi200369f4}

Thyroid Cancer Death {#H2-5-ZOI200369}
--------------------

As presented in eTable 4 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}, the country with the highest ASDR was Ethiopia (2.24; 95% UI, 1.46-3.21) in 1990 and the Philippines (1.55; 95% UI, 1.33-1.82) in 2017. The ASDR decreased most in Qatar (total: EAPC, −5.95; 95% CI, −6.52 to −5.37: females: EAPC, −7.08; 95% CI, −6.36 to −7.80) and increased most in Armenia (total: EAPC, 4.13; 95% CI, 3.12-5.15; females: EAPC, 4.29; 95% CI, 3.28-5.32; males: EAPC, 3.84; 95% CI, 2.83-4.85) and South Korea (total: EAPC, 3.70; 95% CI, 2.48-4.93; females: EAPC, 3.53; 95% CI, 2.13-4.93; males: EAPC, 4.10; 95% CI, 3.21-4.99). The ASDR decreased most in Kazakhstan (EAPC, --3.96; 95% CI, −4.33 to --3.58) among males. For females, the country with the highest ASDR changed from Ethiopia (2.72; 95% UI, 1.65-3.86) in 1990 to the Philippines (1.97; 95% UI, 1.60-2.44) in 2017; for males, it was the Maldives (1.93 in 1990 and 1.37 in 2017). The EAPC was positively correlated with ASDR (ρ = 0.28, *P* \< .01) ([Figure 3](#zoi200369f3){ref-type="fig"}B) and negatively correlated with SDI (ρ = --0.17, *P* = .02) (eFigure 9 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

South Asia (3630 in 1990 and 8930 in 2017) and Oceania (20 in 1990 and 50 in 2017) had the largest and smallest numbers of thyroid cancer deaths, respectively (eTable 1 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). As presented in eTable 6 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}, the ASDR increased most in Andean Latin America (total: EAPC, 1.08; 95% CI, 0.85-1.31; females: EAPC, 0.99; 95% CI, 0.78-1.19) and decreased most in Central Europe (total: EAPC, −2.15; 95% CI, −2.35 to −1.96; females: EAPC, −2.20; 95% CI, −2.36 to −2.04; males: EAPC, −2.08; 95% CI, −2.38 to −1.79). The ASDR of males increased most in East Asia (EAPC, 2.32; 95% CI, 1.94-2.70).

As reported in eTable 1 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}, the deaths from thyroid cancer increased in all SDI quintiles, but ASDRs increased only in the middle (EAPC, 0.33; 95% CI, 0.25-0.41) and low-middle (EAPC, 0.28; 95% CI, 0.23-0.33) SDI quintiles. From 1990 to 2017, the SDI quintile with the highest deaths had changed from high SDI (6900; 95% UI, 6810-6990) to middle SDI (11 610; 95% UI, 11 040-12 890). The low SDI quintile had the lowest number of deaths (2400 in 1990 and 4530 in 2017) and highest ASDRs (0.65 in 1990 and 0.62 in 2017). The ASDR decreased the most in the high SDI quintile (EAPC, −0.68; 95% CI, −0.74 to −0.62). Deaths associated with thyroid cancer in the high and high-middle SDI quintiles occurred mainly in persons older than 70 years; in other SDI quintiles, deaths were mainly in those aged 15 to 69 years (eg, high SDI: EAPC, −1.03; 95% CI, −1.09 to −0.97) (eTable 6 and eFigures 10-15 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). The ASDRs of females decreased in all SDI quintiles. For males, the ASDR increased in all but the high SDI quintile (EAPC, −0.09; 95% CI, −0.18 to −0.01) (eTable 6 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). However, from 2010, the ASDRs of males in all SDI quintiles started decreasing (high SDI, EAPC: −1.1; 95% CI, −1.2 to −0.9; high middle SDI, EAPC: −0.5; 95% CI, −1.1 to −0.2; middle SDI, EAPC: −0.2; 95% CI, −0.6 to 0.3; low-middle SDI, EAPC: −0.2; 95% CI, −0.7 to 0.3; low SDI, EAPC: −0.6; 95% CI, −0.9 to −0.3) (eFigures 16-18 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). Thyroid cancer--associated deaths were seen most in people older than 70 years and showed a slightly increasing trend (high SDI, EAPC: −1.1; 95% CI, −1.2 to −0.9; high middle SDI, EAPC: −0.5; 95% CI, −1.1 to 0.2; middle SDI, EAPC: −0.2; 95% CI, −0.6 to 0.3; low-middle SDI, EAPC: −0.2; 95% CI, −0.7 to 0.3; low SDI, EAPC: −0.6; 95% CI, −0.9 to −0.3) (average annual percentage change, 0.10; 95% CI, 0.01-0.21; *P*\<.05), followed by age 50 to 69 years (eFigure 19 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

Thyroid Cancer DALYs {#H2-6-ZOI200369}
--------------------

As shown in eTable 5 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}, females in India (63 063.09 in 1990 and 124 747.31 in 2017) and males in China (36 108.73 in 1990 and 97 467.41 in 2017) had the highest DALYs. The country with the highest age-standardized DALY rate changed from Ethiopia (67.28; 95% UI, 40.33-99.04) in 1990 to Pakistan (42.46; 95% UI, 31.33-58.20) in 2017. The age-standardized DALY rate decreased most in Qatar (EAPC, −4.59; 95% CI, −5.02 to −4.16) and increased most in South Korea (total: EAPC, 5.49; 95% CI, 4.18-6.82; females: EAPC, 5.66; 95% CI, 4.16-7.19; males: EAPC, 5.52; 95% CI, 4.50-6.55). The age-standardized DALY rate decreased most in Qatar among females (EAPC, −6.36; 95% CI, −7.02 to −5.68) and in Kazakhstan among males (EAPC, −4.13; 95% CI, −4.52 to −3.73). In addition, the EAPC was correlated with ASIR (ρ = −0.35, *P* \< .01) ([Figure 3](#zoi200369f3){ref-type="fig"}A) but was not correlated with SDI (ρ = −0.08, *P* = .29) (eFigure 20 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

The region with the highest DALYs of thyroid cancer changed from East Asia (104 010) in 1990 to South Asia (297 710) in 2017. Conversely, the number of DALYs in Oceania remained the lowest (770 in 1990 and 1670 in 2017) (eTable 2 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). The age-standardized DALY rate increased most in the high-income Asia-Pacific area (total: EAPC, 1.45; 95% CI, 0.99-1.91; females: EAPC, 1.34; 95% CI, 0.83-1.90; males: EAPC, 1.79; 95% CI, 1.40-2.19), and decreased most in Central Europe (EAPC, −2.03; 95% CI, −2.24 to −1.83). The EAPC was the lowest in Eastern sub-Saharan Africa (EAPC, −2.04, 95% CI, −2.20 to −1.88) among females and Central Europe among males (EAPC, −2.10; 95% CI, −2.38 to −1.82) (eTable 6 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

From 1990 to 2017, the SDI quintile with the highest DALYs changed from the high SDI (162 780) to the middle SDI quintile (314 770), while the lowest DALYs remained in the low SDI quintile (89 840 in 1990 and 153 320 in 2017) (eTable 2 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). The EAPCs among females in all SDI quintiles were less than zero. The EAPCs among males were positive in all SDI quintiles except for the high SDI (EAPC, 0.03; 95% CI, −0.09 to 0.15) (eTable 6 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). However, the age-standardized DALY rates of males in all SDI quintiles started decreasing in 2010 (eFigures 21-23 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}). In the high SDI quintile, the DALYs were concentrated in the age groups older than 50 years and 50 to 69 years in the high-middle and middle SDI quintiles, and in the age group of 15 to 49 years in the low-middle and low SDI quintiles (eFigures 24-29 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

The DALYs of global thyroid cancer were seen mainly among individuals aged 50 to 69 years, followed by 15 to 49 years. From 1990 to 2017, the proportion of DALYs in individuals older than 70 and 50 to 69 years increased, while those noted in the age groups of 15 to 49 and 5 to 14 years decreased (eFigure 30 in the [Supplement](#note-ZOI200369-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI200369}
==========

In this study, from 1990 through 2017, the incidence, deaths, and DALYs of thyroid cancer and ASIR increased by 60% to 200%, whereas the ASDR and age-standardized DALY rates decreased. The increasing incidence of thyroid cancer in all SDI quintiles raises notable points. The ASIR in areas within a high SDI quintile continued to increase until 2010 and then began decreasing. Compared with the decreased age-standardized rates among females in all SDI quintiles, those rates among males continued to increase until 2010. In 2009, the American Thyroid Association's guidelines on thyroid cancer diagnosis and treatment were revised substantially and other countries developed guidelines, which might be associated with the change noted from 2010.^[@zoi200369r20]^ A previous study reported that males in communities with low socioeconomic status had poorer thyroid cancer--specific survival, but these findings did not appear to apply to women.^[@zoi200369r21]^ Similarly, Nilubol et al^[@zoi200369r22]^ suggested that males with thyroid cancer presented at an older age and had more advanced and aggressive disease, which is consistent with our results that the main age at onset of thyroid cancer in females (15-49 years) was younger than in males (50-69 years). Men appear to have advanced thyroid cancer at the time of diagnosis, leading to earlier cause-specific deaths associated with thyroid cancer^[@zoi200369r23]^ possibly owing to sex differences in biology and behavioral attitudes in seeking medical care.^[@zoi200369r24]^ However, established risk factors, such as radiation exposure and a family history of thyroid cancer, could not explain the increased incidence.^[@zoi200369r25]^ There was no significant association between reproductive factors (menstrual, reproductive, or hormonal history) and thyroid cancer risk.^[@zoi200369r23],[@zoi200369r26],[@zoi200369r27]^ Another study noted differences in the expression of estrogen receptor subtypes based on thyroid cancer histologic factors.^[@zoi200369r28]^

Almost half of the incident cases of thyroid cancer were in Southern and Eastern Asia, which may be partly associated with the large population base. In South Korea, the increased incidence, ASIR, and age-standardized DALY rate were almost the highest seen in all regions; this increase might be associated with a cancer screening program begun there in 1999 that showed a 15-foled increase in the incidence of diagnosis of thyroid cancer.^[@zoi200369r29],[@zoi200369r30]^ This increasing incidence of thyroid cancer in South Korea is an example of the change in health care policy. Most of the DALYs associated with thyroid cancer were also noted in Asia, where most middle- and low-middle SDI countries are located. Findings from Korea suggested that thyroid cancer has become 1 of the 3 most significant cancers affecting DALYs, which may have continued during 2000-2020.^[@zoi200369r31]^ An analysis from the US Preventive Services Task Force^[@zoi200369r32]^ observed that harms of thyroid cancer screening outweighed the benefits.^[@zoi200369r29],[@zoi200369r33]^ Thyroid cancer is one of the most overdiagnosed and overtreated cancers^[@zoi200369r34]^; however, overdiagnosis and overtreatment may not fully explain the cause of the increase in thyroid cancer burden. In Fukushima, Japan, the results of the thyroid ultrasonographic examination program may have been affected by a combination of overdiagnosis and radiation exposure.^[@zoi200369r35]^ Therefore, policy makers there should consider the contemporary etiologic data, treatment information, iodine nutrition status, and living environment to establish targeted and specific strategies.

The anxiety of patients may lead to overtreatment, such as total thyroidectomy and thyroid replacement therapy, accompanied by various adverse effects, including hypoparathyroidism and vocal cord paralysis, as noted by McLeod et al.^[@zoi200369r36]^ In addition, a Japanese study suggested that there is no substantial difference between immediate surgery and watchful waiting in preventing deaths from thyroid cancer.^[@zoi200369r37]^ Therefore, for small papillary nodules, active periodic surveillance may be a reasonable and correct choice. The proportion of thyroid cancer deaths among individuals older than 70 years increased significantly, whereas the proportions of death among 3 other age groups decreased, which might be due to the improvement of treatment and aging of the population.^[@zoi200369r38]^ In our study, the low SDI quintile presented the lowest number of deaths and highest DALYs associated with thyroid cancer. Nevertheless, the reason for the relatively low burden of thyroid cancer in districts with lower SDI cannot exclude the lack of advanced medical services and accurate laboratory investigations. The main age group in which thyroid cancer was associated with mortality was proportional to the SDI value, similar to the gap in medical standards and income worldwide.^[@zoi200369r39],[@zoi200369r40],[@zoi200369r41],[@zoi200369r42]^

To our knowledge, this study presents the latest epidemiologic patterns of thyroid cancer burden at global, regional, and national levels among different sex, age, and SDI categories. Asia apparently carries the heaviest burden of thyroid cancer, while Oceania has the lowest. The most common onset age in persons who developed thyroid cancer decreased, and the age at death of those with thyroid cancer increased worldwide. Furthermore, people in lower SDI quintiles developed thyroid cancer and died from it earlier than those in other quintiles. In addition, growth patterns were significantly different between sexes and seemed to be reversed in the later years of the study. In our analysis, epidemiologic profiles of the thyroid cancer burden showed large heterogeneities. Investments in cancer prevention and treatment need to recognize the interdependence between socioeconomic status and health. To ensure balanced development of health services in all countries, greater efforts are needed to reduce these health inequities. Our research may provide data to support policy makers and other stakeholders in efforts to achieve equitable allocation of health care resources.

Limitations {#H2-7-ZOI200369}
-----------

This study has limitations. As with other estimates of disease burden, the most important limitation of GBD is the lack of data at many sites. The key principle of GBD is to make full use of the data sources of all relevant resources. Data are available from a wide range of sources (\>90 000 data sources). Although the diagnosis of thyroid cancer with inadequate, insufficiently specific, or unreliable registration has been corrected by a redistribution algorithm, the accuracy of diagnosis still has some unreliability. In addition, information bias regarding the epidemiologic evaluation of thyroid cancer was inevitable, as data are scarce in a few parts of the world. Given the restrictions of data type, to our knowledge, further investigation on thyroid cancer stratified by histologic characteristics, grade, and risk factors has not been conducted.

Conclusions {#H1-5-ZOI200369}
===========

In this study, the incidence, deaths, DALYs, and ASIR for thyroid cancer appeared to increase globally, signifying a larger burden on global health care systems, especially in females and countries with a high SDI. Nevertheless, the ASDR and age-standardized DALY rate in thyroid cancer decreased, which may be associated with improvement in therapeutic approaches. The thyroid cancer burden was largely heterogeneous across various categories evaluated, possibly reflecting differences in the corresponding genetic and environmental risk factors, as well as levels of economic status, education, lifestyle, and access to medical screening and therapeutic care. These factors need further investigation to ascertain detailed mechanisms.
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